The design of nano-drug delivery vehicles responsive
to tumor microenvironment
stimuli has become a crucial aspect in developing cancer therapy in
recent years. Among them, the enzyme-responsive nano-drug delivery
system is particularly effective, as it utilizes tumor-specific and
highly expressed enzymes as precise targets, leading to increased
drug release at the target sites, reduced nonspecific release, and
improved efficacy while minimizing toxic side effects on normal tissues.
NAD(P)H:quinone oxidoreductase 1 (NQO1) is an important reductase
associated with cancer and is overexpressed in some cancer cells,
particularly in lung and breast cancer. Thus, the design of nanocarriers
with high selectivity and responsiveness to NQO1 is of great significance
for tumor diagnosis and treatment. It has been reported that under
physiological conditions, NQO1 can specifically reduce the trimethyl-locked
benzoquinone structure through a two-electron reduction, resulting
in rapid lactonization via an enzymatic reaction. Based on this, a
novel reduction-sensitive polyurethane (PEG-PTU-PEG) block copolymer
was designed and synthesized by copolymerizing diisocyanate, a reduction-sensitive
monomer (TMBQ), and poly(ethylene glycol). The successful synthesis
of monomers and polymers was verified by nuclear magnetic resonance
(1H NMR) and gel permeation chromatography (GPC). Then,
the PEG-PTU-PEG micelles were successfully prepared by self-assembly,
and their reductive dissociation behavior in the presence of Na2S2O4 was verified by dynamic light scattering
(DLS), 1H NMR, and GPC. Next, the model drug doxorubicin
(DOX) was encapsulated into the hydrophobic core of this polyurethane
micelles by microemulsion method. It was observed that the drug-loaded
micelles could also achieve a redox response and rapidly release the
encapsulated substances. In vitro cell experiments
demonstrated that PEG-PTU-PEG micelles had good biocompatibility and
a low hemolysis rate (<5%). Furthermore, in the presence of an
NQO1 enzyme inhibitor (dicoumarol), lower drug release from micelles
was observed in A549 and 4T1 cells by both fluorescence microscopy
and flow cytometry assays, but not in NIH-3T3 control cells. Predictably,
DOX-loaded micelles also showed lower cytotoxicity in 4T1 cells in
the presence of NQO1 enzyme inhibitors. These results indicate that
drug-loaded polyurethane micelles could accomplish specific drug release
in the reducing environment in the presence of NQO1 enzymes. Therefore,
this study provides a new option for the construction of polyurethane
nanocarriers for precise targeting and reductive release, which could
benefit the intracellular drug-specific release and precision therapy
of tumors.